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Abstract
We have reported that the radical scavenger XJB-5-131 attenuates or reverses progression
of the disease phenotype in the HdhQ(150/150) mouse, a slow onset model of HD. Here,
we tested whether XJB-5-131 has beneficial effects in R6/2 mice, a severe early onset
model of HD. We found that XJB-5-131 has beneficial effects in R6/2 mice, by delaying fea-
tures of the motor and histological phenotype. The impact was sex-dependent, with a stron-
ger effect in male mice. XJB-5-131 treatment improved some locomotor deficits in female
R6/2 mice, but the effects were, in general, greater in male mice. Chronic treatment of male
R6/2 mice with XJB-5-1-131 reduced weight loss, and improved the motor and temperature
regulation deficits, especially in male mice. Treatment with XJB-5-131 had no effect on the
lifespan of R6/2 mice. Nevertheless, it significantly slowed somatic expansion at 90 days,
and reduced the density of inclusions. Our data show that while treatment with XJB-5-131
had complex effects on the phenotype of R6/2 mice, it produced a number of significant
improvements in this severe model of HD.
Introduction
XJB-5-131 is a bi-functional synthetic antioxidant comprising a delivery component conju-
gated to an antioxidant moiety (Fig 1)[1–4]. This peptide mimetic portion of XJB-5-131 (Fig 1,
red) directly targets the mitochondrial membrane and delivers the antioxidant nitroxide (Fig
1, blue) to neutralize reactive radical species [5]. XJB-5-131 has profound beneficial effects in
offsetting the effects of oxidative damage [2, 6–9]. We have previously reported the effects of
XJB-5-131 in the HdhQ(150/150)mouse model of Huntington’s disease [8–10], which carries a
disease-length 150 CAG tract knocked into both full-length endogenous alleles [11]. These
mice develop pathophysiology slowly. HdhQ(150/150) animals typically live as long as their
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wild-type counterparts, but develop features of disease at approximately 20–25 weeks for
homozygotic mice and upwards of 60 weeks for heterozygotic mice [11–14]. When treatment
was started before the phenotype developed (7 weeks of age), XJB-5-131 attenuated the decline
in rotarod performance, suppressed weight loss, and increased the copy number of mitochon-
drial DNA in HdhQ(150/150)mice [9]. XJB-5-131 also attenuated decline or reversed the
effects of disease if treatment began after disease onset at 60 weeks of age [8]. In ageing animals
with well-developed pathology, XJB-5-131 treatment promoted weight gain, attenuated neuro-
nal loss, reduced inclusion formation, prevented decline in performance in multiple motor
tests, and decreased oxidative damage in the brains of aging HdhQ(150/150) animals relative to
age-matched vehicle-treated HdhQ(150/150)mice [8]. XJB-5-131 also reduced the level of
8-oxo-guanine and of cardiolipin oxidation in treated mice [6, 8, 15]. Cardiolipin is an impor-
tant component of the inner mitochondrial membrane, and is essential for the proper func-
tioning of numerous enzymes and optimal mitochondrial energy metabolism [16].
In contrast to full-length mouse models, fragment HD model mice express only an N-termi-
nal polyglutamine portion of the HD disease gene. The most commonly used of these models is
Fig 1. The structure of XJB-5-131. XJB-5-131 is a bi-functional antioxidant comprising a delivery component
conjugated to an antioxidant moiety [1, 4]. The delivery portion of the molecule is an alkene peptide isostere
modification of the Leu-D-Phe-Pro-Val-Orn segment of the antibiotic gramicidin S (red) [15]. This peptide mimetic
directly targets the mitochondrial membrane and delivers the antioxidant nitroxide, 2,2,6,6-tetramethyl piperidine-
1-oxyl (TEMPO) (blue), to neutralize reactive radical species.
https://doi.org/10.1371/journal.pone.0194580.g001
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the R6/2 line [17–20]. The R6/2 mouse phenotype is particularly acute in the line with ~140
repeats, presenting with overt symptoms at 9–11 weeks and dying by 13–18 weeks [17]. The
CAG repeat tract in the 5’ exon 1 coding sequence of both R6/2 and the related R6/1 lines of HD
mouse is unstable [19, 21–25]. While the transgene original founder retained a CAG tract of
~144 repeats [16, 19], mice with repeats longer than 350 develop phenotypes later, and survive
longer, than those with shorter repeats [21, 26, 27].
Because R6/2 mice develop a severe, progressive behavioural phenotype that mimics early
onset aspects of HD pathophysiology [17–20], we were interested in finding out if XJB-5-131
could ameliorate phenotypic signs of HD in R6/2 mice. The R6/2 mice were tested for changes
in overall physiology and behaviour in a series of behavioural tests. Here, we report that XJB-
5-131 has beneficial effects in R6/2 mice. Consistent with its role as an oxygen radical scaven-
ger, XJB-5-131 suppressed age-dependent somatic CAG expansion in both male and female
R6/2 mice. The impact of XJB-5-131 on the outcome of behavioural testing was sex-dependent,
with male mice showing greater improvement.
Materials and methods
Mice
This research was regulated under the Animals (Scientific Procedures) Act 1986 Amendment
Regulations 2012, and following ethical review and approval by the University of Cambridge
Animal Welfare and Ethical Review Body. Mice were taken from colonies of R6/2mice estab-
lished in the University of Cambridge, and maintained by backcrossing onto CBA x C57BL6 F1
female mice. Genotyping methods and detailed husbandry for R6/2 animals have been described
previously [20, 26]. Briefly, mice were housed in single-sex, single-genotype groups of 8–10 at
21–23˚C with humidity of 55 ± 10%. Lowered waterspouts were provided for ad libitum access
to water and standard dry laboratory food was given. A supplementary feed (of mash made by
soaking 100g dry food in 230 ml of tap water until pellets were fully expanded) was given each
morning and evening. Enrichment was provided by the addition of plastic houses, cardboard
tubes and chew blocks to the cages. Mice lived under a 12hr/12hr light/dark cycle, with lights on
at 7am and off at 7pm. Genotyping and CAG repeat length measurement were carried out by
Laragen (Los Angeles, CA, USA). CAG repeat lengths of the transgenic mice were 255 ± 1
(mean ± SEM), as determined by GeneMapper. Mice were divided into 6 groups: R6/2 male
drug-treated (n = 7) (hereafter referred to as R6/2-XJB male); R6/2 female drug-treated (n = 9)
(R6/2-XJB female); R6/2 male vehicle-treated (n = 8) (R6/2-Veh male); R6/2 female vehicle-
treated (n = 8) (R6/2-Veh female); WT male vehicle-treated (n = 8) (WT-Veh male); and WT
female vehicle-treated (n = 8) (WT-Veh female).
XJB-5-131 preparation
XJB-5-131 was synthesized as previously reported [8, 9]. XJB-5-131 was stored as powder at
-80˚C. At the beginning of the experiment, lyophilized, powdered XJB-5-131 was reconstituted
in DMSO at a concentration of 1 mg/μL, as previously described [8]. On each dosing day, the
XJB-5-131 solution was mixed with filtered and pre-heated PBS (100˚C), and heated for 10
seconds. The final concentration was 2mg/kg mouse body weight in a 200 μL volume. The
solution was injected within 30 minutes of preparation.
Drug treatment
WT or R6/2 animals were treated with either XJB-5-131 (XJB) or the saline vehicle (Veh). We
have previously published that XJB-5-131 has little effects on WT animals [8]. Thus, we focused
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here on the impact of XJB-5-131 on improving the phenotype of R6/2 mice, using WT-Veh as a
control. XJB-5-131 or vehicle was administered intraperitoneally every second day. Dosing was
carried out in the evening. On days where behavioural testing was being conducted, dosing was
done after testing to avoid detecting acute drug effects. XJB-5-131 and vehicle were aliquoted
into coded bottles to avoid bias. Drug treatment began at 4 weeks of age.
Behavioural assessments
All behavioural testing was performed at the same time of day by the same experimenter. At
the beginning of the experiment, all behavioural testing was carried out blind to genotype. As
the phenotype became apparent, this was no longer possible. A timeline of the behavioural
assessments is shown (Fig 2).
Body temperatures
Implantable electronic transponders (IPTT300, Bio Medic Data Systems Inc., Seaford, DE)
were injected subcutaneously between the scapulae of mice at 6 weeks of age. Temperatures
were recorded every second day before drug/vehicle administration, and averaged over each
week, to eliminate the confounding effect of day-to-day variations in individual mice.
Body weights
Body weights were recorded every second day from 4 weeks of age. Weights were taken before
drug/vehicle administration at the same time as temperature recording, and averaged over
each week, to eliminate the confounding effect of day-to-day variations in individual mice.
Accelerating rotarod
Mice were tested once on the accelerating rotarod (Ugo Basile, Varese, Italy) task at 12 weeks
of age. Each mouse received 2 training trials per day for 4 days. Each training trial consisted of
placing the mouse on the rod rotating at a speed of 24 rpm for 60s. For the test itself, mice
were placed on the rotarod, which was accelerated from 4–40 rpm over a 10 minute period.
The latency to fall or step off the rotarod was calculated as an average of 3 trials. Inter-trial
intervals were 45–50 min for each mouse.
Fig 2. Timeline of behavioural study.
https://doi.org/10.1371/journal.pone.0194580.g002
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Fixed speed rotarod
Mice were tested on the fixed speed rotarod on the day after completing the accelerating
rotarod procedure. Each mouse was given 2 successive trials at each of 7 different speeds (5, 8,
15, 20, 24, 31, 33 and 40 rpm). At each speed, the latency to fall off the rotarod (maximum 60s)
was recorded, and the average of both trials at each speed was used for the analysis. Inter-trial
intervals were 5–10 min for each mouse.
Open field test
Mice were evaluated in the open-field task as described by Carter et al. [17]. Briefly, mice were
placed individually in an open-topped plastic box 60 × 60 × 30 cm high, with white walls and
floor. The floor was marked with black gridlines (divided into 25 squares (‘cells’), each measur-
ing 12 × 12 cm). The middle nine cells were called the centre, the outer ‘ring’ of cells was called
the periphery. Individual mice were placed in the central cell of the open field and observed for
a 10 minute period. Parameters measured included: (1) latency to reach the periphery; (2) total
number of central cells entered (defined as three or more paws moving into a central cell); (3)
total number of peripheral cells entered (defined as three or more paws moving into a periph-
eral cell); (4) total number of cells entered; (5) total incidences of supported rearing (standing
up on hind legs using the wall for support); (6) total incidences of unsupported rearing (stand-
ing up on hind legs without wall support); (7) number of complete grooming cycles; (8) number
of faecal boli; and (9) number of urinations. Mice were tested at 7, 12 and 17 weeks.
LABORAS
Normal mouse behaviours were measured over 48 hours in the LABORAS (Laboratory Ani-
mal Behaviour, Observation, Registration and Analysis System) apparatus (Metris b.v., Hoofd-
dorp, The Netherlands). The LABORAS apparatus measures locomotor activity, immobility,
grooming, eating, drinking and climbing. During the monitoring period mice were singly
housed with ad libitum access to food and water. For each mouse, testing was carried out
twice, at 8 and 14 weeks of age. Following testing, the mice were returned to their home cages.
SHIRPA assessment and hangwire score
The general physical condition of the mice was assessed at 6, 12 and 16 weeks using a modified
SHIRPA (SmithKline Beecham Pharmaceuticals; Harwell, MRC Mouse Genome Centre and
Mammalian Genetics Unit; Imperial College School of Medicine at St Mary’s; Royal London
Hospital, St Bartholomew’s and the Royal London School of Medicine Phenotype Assessment)
protocol [28, 29]. Briefly, mice were assessed for hair and tail morphology, piloerection, pres-
ence/absence of whiskers, domed face and lordokyphosis, respiration rate, palpebral closure,
color of eye fur, fluidity of gait, pelvic elevation, tail elevation, touch escape, positional passiv-
ity, forelimb and hindlimb clasping, aggression, vocalisation, tremor, grip strength, initial
activity and righting reflex. Data were quantified using a graded scoring system, where normal
behaviour received a score of 0. A global score was determined for each mouse, with the high-
est scores corresponding to the greatest degree of abnormality. Grip strength was measured as
part of the SHIRPA screen, using the hangwire test. Individual mice were placed on a wire
cage lid and the lid was gently moved back and forth until the mouse gripped the wire. The lid
was then turned upside down, 15cm above the surface of the bedding material. Latency to fall
onto the bedding was recorded, with a 60s cut-off time.
XJB-5-131 relieves Huntington’s disease
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Glycosuria
Mice were placed in a clean, sawdust-free cage. Most mice urinated spontaneously, but where
necessary, gentle handling was used to induce micturition. The urine was tested with Diastix
reagent strips (Bayer plc, Newbury, UK), which enables a semi-quantitative analysis of glycos-
uria. The presence of glycosuria was regarded as indicative of diabetic status. Mice were tested
at 12 and 16 weeks of age.
Somatic expansion
The size distribution of CAG repeats was established using GeneMapper [30] and the signifi-
cance was determined by the method previously reported [10]. The age-dependent somatic
changes among treated and untreated groups were normalized by subtracting the CAG tracts
measured at birth from the CAG tracts measured at 12 weeks. The distributions were expressed
as the change in repeat length and summed from all animals within a treatment group to create
a single global distribution that characterized the population. Using these global distributions,
somatic expansions in the striatum and cerebellum were a measure of the overall changes in
repeat length in treated or untreated groups. The distributions at 12 weeks were divided into
100 cells (quantile analysis), excluding the first and last 5 quantiles, and the length of peaks in
each cell was averaged, and the difference in the means of treated and untreated animals were
subtracted. Data were expressed as a comparison between treated versus the untreated. The
means between groups were performed using one-way analysis of variance (ANOVA) with the
categories of treatment or age as independent factors. For analyses of means involving the
treated and untreated groups, the F-test was used to determine whether the variances between
the two groups were significantly different. For samples with a significant difference in variance,
the Welch’s t-test was applied. Student’s t-test was applied for the samples with an insignificant
difference in variance. The significance level was set at 0.05 for all analyses. All statistical analysis
computations were carried out using Prism (Graphpad Software).
Survival
Age of death was recorded for all R6/2 mice. Mice were killed when they reached end-point–if
they were moribund, lacked a righting reflex, or failed to respond to gentle stimulation.
Tissue analysis
Subsets of mice (n = 2 per group) were killed for histology at 8 and 12 weeks.
Histology
Primary antibodies used were mouse anti-NeuN Alexa488 conjugate (Millipore #MAB377X)
(used at 1:400), mouse anti-GFAP Cy3 conjugate (Abcam #ab49874) (used at 1:400, and rabbit
anti-Ubiquitin (DAKO #Z0458) (used at 1:400). Secondary antibodies used were goat anti-rabbit
Alexa-555 conjugated (Invitrogen #A31630) (used at 1:400), goat anti-mouse Alexa-488 conju-
gated (Invitrogen #A31620) (used at 1:400). Brain sections cryoembedded in OCT were sliced
(10 μm thick using a Leica Cryostat set at: -14˚C for the sample and -12˚C for the blade) and
placed onto Histobond microscope slides (VWR). They were immediately fixed and OCT
removed in 100% methanol (10min). Samples were rehydrated sequentially in 75%, 50%, 25% and
0% ethanol in PBS (2min each). Tissue was treated with Image-iT FX signal enhancer (Thermo-
Fisher #I36933) to reduce autofluorescence (30min) and blocked (2-18hrs) in blocking solution
(PBS, 3% BSA, 5% goat serum, 0.7% donkey serum, 0.03% triton X-100). Antibody staining was
performed overnight, followed by 3 washes with PBS (5min ea.). Secondary antibody was applied
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later as required along with 0.5 μM DAPI (1-2hrs) followed by 3 washes in PBS. Slides were coated
with Vectashield+DAPI, sealed with a coverslip and stored (-20˚C) until they were imaged. Slides
were imaged using a Zeiss 710 confocal microscope using either of 20x(0.8N/A)/air, 40x(1.2N/A)/
water or 100x(1.4N/A)/oil lenses. Image analysis was carried out using ImageJ:Fiji [31].
GeneMapper analysis of somatic CAG expansion
DNA was prepared from frozen mouse tissues and CAG repeat sizing performed by Laragen
(Culver City, CA, U.S.A.), as previously reported [23].
Statistics for behaviour tests
Statistical analyses were performed using Statsoft Statistica v11 software (Statsoft, Tulsa, OK,
USA) or Prism 5 (GraphPad Software Inc., San Diego, CA, USA). For statistical analysis of
behavioural testing, body weights and temperatures, we used repeated measures ANOVA with
sex, treatment and genotype as factors. Bonferroni’s post hoc test was used to determine spe-
cific differences, when significant group effects were found. Survival data were compared
using the log-rank test. Significance levels were set at p<0.05 for all analyses. Data were not
collated and analysed until the end of the experiment. Behavioural testing was performed in
the University of Cambridge, while the somatic expansion analysis and tissue analysis was per-
formed in Lawrence Berkeley Laboratory. The results were shared upon completion of analy-
ses in both laboratories.
Results
XJB-5-131 treatment reduces loss of body temperature in R6/2 mice
Analysis of body temperature data suggested that there were three distinct phases of disease in
the mice. In the early stages of the study (7–11 weeks of age), the body temperature of R6/2 male
mice was higher than WT mice (Fig 3A), suggesting a higher resting metabolic rate (WT-Veh
vs R6/2-Veh, p<0.05; WT vs R6/2-XJB, p<0.01). There was no effect of XJB-5-131 treatment
(R6/2-Veh vs R6/2-XJB, p>0.05). Between 12–17 weeks of age, R6/2 male mice no longer had a
higher body temperature than WT male mice (all group comparisons, p>0.05). As the pheno-
type became more pronounced from 18 weeks onwards, the body temperatures of R6/2 mice
decreased (Fig 3A). Treatment with XJB-5-131 suppressed the drop in temperature (p<0.05).
Female mice showed no genotype or treatment effect on body temperatures at either 7–11
or 12–17 weeks (all comparisons, p>0.05). As seen with the male mice, body temperatures of
R6/2 female mice decreased after 18 weeks, when the phenotype was evident (Fig 3B). Between
18–22 weeks, XJB-5-131 treatment reduced the fall in temperature in R6/2 mice (p<0.05). R6/
2-Veh mice were colder than WT and R6/2-XJB mice (both comparisons, p<0.05, (Fig 3B),
with no difference in body temperature between WT and R6/2-XJB mice.
XJB-5-131-treated male R6/2 mice maintain weight better than their
vehicle-treated littermates
Weight loss is a feature of both human and mouse HD pathology. We predicted that if XJB-5-
131 treatment was beneficial, it should prevent or slow weight loss in R6/2 mice. At 4 weeks of
age, WT and R6/2 male mice were of a similar weight, but from this age onward R6/2 mice, as
a consequence of the developing phenotype, failed to gain weight at the same rate as their
WT-V littermates (Fig 4). In male mice, there was a biphasic response to drug treatment, with
the tipping point at 13 weeks. Between 4 and 13 weeks of age, XJB-5-131-treated R6/2 male
mice failed to gain weight as quickly as either WT or R6/2-Veh mice (both comparisons,
XJB-5-131 relieves Huntington’s disease
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p<0.01; (Fig 4A). However, from 14 weeks of age onwards, although R6/2-XJB male mice con-
tinued to lose weight, they did so at a slower rate than R6/2-Veh male mice. Female R6/2 mice
Fig 3. XJB-5-131 suppressed the decline in body temperatures in R6/2 mice. Body temperatures were recorded
every 2 days from implanted microchips. Temperatures were then averaged per week. Panel A, male mice only; B,
female mice only. R6/2 mice showed the expected drop in temperatures with age. Treatment with XJB-5-131
maintained temperatures in R6/2mice for longer.  p<0.05,  p<0.01,  p<0.001. Grey symbols, WT; white
symbols, R6/2-Veh; black symbols, R6/2-XJB. Dotted lines indicate the analysis periods. Data are mean ± SEM. Mouse
numbers: 4–8 weeks, WT male, WT female, R6/2-Veh male, R6/2-Veh female, n = 8. R6/2-XJB male, n = 7; R6/2-XJB
female, n = 9. 9–12 weeks, all groups n = 6. 13–17 weeks, all groups n = 4. 18 weeks, all groups except R6/2-Veh male,
n = 4; R6/2-Veh male, n = 3. 19 weeks, WT male, WT female, R6/2-XJB male, n = 4; R6/2-XJB female, n = 3; R6/2-Veh
male, n = 1; R6/2-Veh female, n = 2. 20 weeks, WT male, WT female, n = 4; R6/2-XJB male, R6/2-Veh female, n = 4;
R6/2-XJB female, n = 1; R6/2-Veh male, n = 0. 21 weeks, WT male, WT female, n = 4; R6/2-XJB male, n = 2; R6/2-Veh
female, R6/2-XJB female, n = 1. 22 weeks, WT male, WT female, n = 4; R6/2-XJB male, R6/2-XJB female, n = 1.
https://doi.org/10.1371/journal.pone.0194580.g003
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also displayed a phenotype-induced weight loss, but progression was slower than in male mice
(Fig 4B). Between 4 and 13 weeks of age, all R6/2 female mice, regardless of treatment, failed to
Fig 4. Body weights were recorded every 2 days, and averaged per week. Panel A, male mice only; B, female mice
only. R6/2mice showed the expected reduction in body weight with age. Treatment with XJB-5-131 caused a slight
improvement in maintenance of weight in male (A), but had a detrimental effect in female (B) R6/2mice.  p<0.05, 
p<0.01,  p<0.001. Grey symbols, WT; white symbols, R6/2-Veh; black symbols, R6/2-XJB. Dotted lines indicate the
analysis periods. Data are mean ± SEM. Mouse numbers: 4–8 weeks, WT male, WT female, R6/2-Veh male, R6/2-Veh
female, n = 8. R6/2-XJB male, n = 7; R6/2-XJB female, n = 9. 9–12 weeks, all groups n = 6. 13–17 weeks, all groups
n = 4. 18 weeks, all groups except R6/2-Veh male, n = 4; R6/2-Veh male, n = 3. 19 weeks, WT male, WT female, R6/2-
XJB male, n = 4; R6/2-XJB female, n = 3; R6/2-Veh male, n = 1; R6/2-Veh female, n = 2. 20 weeks, WT male, WT
female, n = 4; R6/2-XJB male, R6/2-Veh female, n = 4; R6/2-XJB female, n = 1; R6/2-Veh male, n = 0. 21 weeks, WT
male, WT female, n = 4; R6/2-XJB male, n = 2; R6/2-Veh female, R6/2-XJB female, n = 1. 22 weeks, WT male, WT
female, n = 4; R6/2-XJB male, R6/2-XJB female, n = 1.
https://doi.org/10.1371/journal.pone.0194580.g004
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gain weight as quickly as WT mice. Unlike in male mice, however, there was no ameliorating
drug effect at later ages, and both drug- and vehicle- treated groups of R6/2 female mice con-
tinued to lose weight at the same rate. Collectively, these data show that, as with body tempera-
ture, the beneficial impact of XJB-5-131 on weight loss in R6/2 animals was sex-dependent,
with male mice responding better to drug treatment.
XJB-5-131 improves performance on the fixed speed rotarod in R6/2 mice
Mice were tested once at 12 weeks on the accelerating rotarod task to measure motor skill (Fig
5A). R6/2 male mice were impaired relative to WT mice regardless of treatment (p<0.001 for
both XJB-5-131- and R6/2-Veh mice). The results for the female mice were similar. R6/2-XJB
female mice (p<0.01) tended to be smaller than R6/2-Veh female mice (p<0.001), but this
phenotype did not reach statistical significance (Fig 5A).
Mice were tested on the fixed speed rotarod at 12 weeks of age (Fig 5B and 5C). The R6/2-Veh
male mice performed poorly relative to WT littermates (p<0.001). However, drug treatment
improved the performance of R6/2-XJB relative to R6/2-Veh male mice at all speeds (Fig 5B);
p<0.001). There was little difference in performance between R6/2-XJB and R6/2-Veh females
(Fig 5B). Thus, treatment with XJB-5-131 produced a sex-dependent effect on the fixed speed
rotarod task, with improvement observed in male mice.
XJB-5-131 improves some behaviours of R6/2 mice in the open field
Mice were assessed in the open field test at 7, 12 and 17 weeks (S1 Table). In R6/2-Veh males
were not distinguishable from WT at 8 weeks. However, behavioural phenotypes developed at
later ages. In R6/2-Veh males, the pathlength travelled was shorter than that of WT male mice
at 12 weeks (p<0.05) (S1 Table). By 17 weeks, when the R6/2 phenotype was becoming appar-
ent, R6/2-Veh animals reared less frequently against walls and produced less faecal boli relative
to WT animals (both comparisons, p<0.001). However, there was no beneficial effect of XJB-
5-131 treatment in male animals (S1 Table).
Female R6/2-Veh had few behavioural differences relative to WT animals in the open field.
Female R6/2-XJB mice produced fewer faecal boli than either WT (p<0.001) or R6/2-Veh
mice (p<0.05), suggesting an XJB-5-131-mediated reduction in anxiety in female mice (S1
Table). Thus, XJB-5-131 produced an improvement in some but not all elements of the pheno-
type, (S1 Table).
Treatment with XJB-5-131 temporarily improves SHIRPA scores in R6/2
mice
Mice were assessed for a battery of tests to monitor their overall physiological decline at 6, 12,
and 16 weeks. SHIRPA is a general measure of physiology derived from the results of a number
of behavioural tests. Test results were quantified using an overall global, graded score, where
normal behaviour received a score of 0 and the highest scores corresponding to the greatest
degree of abnormality and considered as a measure of overall physiological. At 6 weeks, R6/2-
Veh mice of both sexes had higher SHIRPA scores than WT mice, consistent with deterioration
in the disease animal (Fig 6). XJB-5-131 treatment improved the phenotype at 6 weeks in both
male and female R6/2 mice (R6/2-XJB, males, p<0.01; females, p<0.05, (Fig 6A), as indicated
by the reduction in the SHIRPA score. However, as disease progressed, the beneficial effect of
XJB-5-131 was lost in both sexes (Fig 6B and 6C). Grip strength was measured by the hangwire
test, where the longer latency to fall indicated an improvement in motor function. Grip strength
deteriorated in R6/2-Veh mice relative to WT mice by 12 weeks, and continued to decline as
XJB-5-131 relieves Huntington’s disease
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Fig 5. Mice were tested on the accelerating (A) and fixed speed (B, C) rotarod tasks at 12 weeks of age. All R6/2
mice were impaired at the accelerating rotarod task relative to WT mice (A). R6/2male mice showed the same level of
impairment regardless of treatment. However, the deficit in XJB-5-131-treated R6/2 female mice was less than in
vehicle-treated mice (A). Both groups of R6/2 male mice were impaired on the fixed speed rotarod task relative to WT
mice (B). However, XJB-5-131-treated male mice performed significantly better than vehicle-treated R6/2 mice (B).
Both groups of R6/2 female mice were impaired relative to WT female mice (C). There was no difference between XJB-
5-131- and vehicle- treated R6/2 female mice, but the difference between the XJB-5-131-treated mice and WT mice
XJB-5-131 relieves Huntington’s disease
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disease progressed in both sexes regardless of treatment (Fig 6D and 6E). Thus, XJB-5-131 was
beneficial at early ages but the benefit was lost as the disease phenotype became severe.
XJB-5-131 did not improve behaviour of R6/2 mice as measured by
LABORAS
Mice were placed in the LABORAS activity monitoring system for 48 hours at 8 and 14 weeks
for automated assessment of locomotor activity, immobility, grooming, eating, drinking and
climbing. LABORAS data were analysed separately from light (7am-7pm) and dark (7pm-
7am) phases, since most activity in mice, being nocturnal, takes place during the dark phase.
Activity in light phase
There were no substantial differences between genotypes detected during the light phase in
either sex regardless of treatment (Table 1).
(p<0.01) was less than between vehicle-treated R6/2 and WT groups (C).  p<0.01,  p<0.001. Grey symbols, WT;
white symbols, R6/2-Veh; black symbols, R6/2-XJB. Data are mean ± SEM. Mouse numbers: n = 6 per group.
https://doi.org/10.1371/journal.pone.0194580.g005
Fig 6. Mice were assessed on the SHIRPA (A, B, C) and hangwire (D, E, F) tests at 6 (A, D), 12 (B, E) and 16 (C, F) weeks of age. At 6 weeks of age, treatment with
XJB-5-131 significantly reduced the deficit seen in vehicle-treated R6/2mice (A). SHIRPA scores were higher in all R6/2 mice relative to WT mice at 12 (B) and 16 (C)
weeks with no beneficial treatment effect at either age. There were no differences in hangwire scores at 6 (D) or 12 (E) weeks, but all R6/2 mice had shorter hangwire
latencies relative to WT mice at 16 weeks (F). However, the impairment was reduced in XJB-5-131-treated R6/2 mice of both sexes, suggesting a slight improvement of
phenotype (F).  p<0.05,  p<0.01,  p<0.001. Data are mean ± SEM. Mouse numbers: 6 weeks, WT male, WT female, R6/2-Veh male, R6/2-Veh female, n = 8. R6/2-
XJB male, n = 7; R6/2-XJB female, n = 9. 12 weeks, all groups n = 6. 16 weeks, all groups n = 4.
https://doi.org/10.1371/journal.pone.0194580.g006
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Activity in dark phase
A genotype effect was more obvious during the dark phase by 8 weeks of age. In both sexes,
WT mice performed better than did R6/2-Veh mice with respect to climbing, locomotor activ-
ity, immobility and grooming (both comparisons, p<0.05; Table 1) (Fig 7A and 7B). Male and
female WT mice continued to perform better at 14 weeks in climbing activity (Table 1), and
females groomed more frequently at this age. However, there were no effects of XJB-5-131
treatment in either sex at any age.
Glycosuria
Several studies have shown that a significant proportion of R6/2 mice gradually develop
increased quantities of sugar in the urine (glycosuria) [32, 33]. Glycosuria was not observed in
any WT mice at either 12 or 16 weeks, but is significantly apparent in the R6/2 line, especially
at 16 weeks. In R6/2 at 12 weeks of age, there was no significant difference between Veh and
XJB male mice in numbers of mice showing glycosuria (Table 2). However, more R6/2 female
mice were diabetic if XJB compared to Veh treated (p<0.01, Table 2). By 16 weeks, there were
no differences in R6/2 mice between Veh and XJB groups, with all mice showing signs of gly-
cosuria (Table 2).
Survival
From 19 weeks onwards, groups of R6/2 mice became smaller as mice were killed due to ill-
health (Table 3). There were no effects of XJB-5-131 on survival in either male (p = 0.1) or
female R6/2 mice (p = 0.6) (Fig 8), (Table 3). No WT mice died from ill-health during the study.
Somatic expansion occurs in both male and female R6/2 animals, and is
suppressed by XJB-5-131 in all brain regions measured
We have shown previously that XJB-5-131 suppresses somatic expansion in HdHQ(150/150)
mice, and delays the onset of toxicity [10]. Thus, we asked whether somatic expansion was sup-
pressed by XJB-5-131 in early onset R6/2 mice, which display severe decline and death between
17–22 weeks [17]. We evaluated 14 mice in a blinded study. When unblinded, the results were
striking. Of 14 mice evaluated (S1 and S2 Figs), expansions were not observed in any mouse at
8 weeks (Fig 9A and 9B), but were prominent at 12 weeks exclusively in R6/2-Veh mice (Fig
9A and 9B). Importantly, XJB-5-131 treatment suppressed expansion in both the striatum and
in the cerebellum of these 12-week R6/2-XJB mice (Fig 9A and 9B)) Quantile statistics con-
firmed that expansions were significantly smaller in treated animal, which was obvious at the
leading edge of the distribution (Fig 9C),and (S2 and S3 Tables) in both the striatum and in
the cerebellum of these animals. The tract lengths were shorter in the treated samples, primar-
ily at the leading edge in both brain regions (Fig 9C), and (S2 and S3 Tables).
Inclusions are suppressed in R6/2 mice by XJB-5-131 in brain regions
measured
Subsets of mice were evaluated for histology (n = 2 per group) at 8 and 12 weeks (Fig 10).
There was no measureable neuronal loss in WT or R6/2-Veh mice in either treatment group of
either sex at 8 weeks, as expected in this line (Fig 10A and 10B). However, independent of sex,
the 12-week R6/2-XJB-5-131 mice had fewer inclusion bodies (both nuclear and cytosolic)
than R6/2-V mice (Fig 10C and 10D). These results suggest that treatment with XJB-5-131 at
2mg/kg in R6/2 mice supressed somatic expansion and had at least some beneficial effect, as
judged by a reduction in a prominent marker for disease progression.
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Table 1. LABORAS analysis of activity at 8 and 14 weeks. Data are total time at each activity over 48 hours (means ± SEM).
8 weeks light phase activity
sex WT-Veh R6/2-Veh R6/2-XJB WT-Veh vs R6/2-Veh WT-Veh vs R6/2-XJB R6/2-Veh vs R6/2-XJB
p value p value p value
Climbing (s) M 2265 ± 683 1506 ± 336 2507 ± 772 0.984 0.999 0.964
F 2039 ± 263 3187 ± 367 2147 ± 368 0.881 0.999 0.901
Locomotion (s) M 1341 ± 177 938 ± 118 1204 ± 229 0.403 0.881 0.667
F 932 ± 90 988 ± 141 954 ± 70 0.962 0.994 0.986
Immobility (s) M 61875 ± 2391 61845 ± 831 61996 ± 1472 0.999 0.999 0.999
F 64704 ± 1195 60449 ± 1611 61362 ± 1157 0.096 0.225 0.89
Rearing (s) M 724 ± 118 1171 ± 74 1311 ± 158 0.441 0.25 0.92
F 630 ± 178 1093 ± 301 1202 ± 166 0.631 0.498 0.974
Grooming (s) M 4508 ± 178 4380 ± 369 4236 ± 741 0.989 0.952 0.986
F 5598 ± 385 5778 ± 607 5437 ± 773 0.978 0.982 0.923
Drinking (s) M 100 ± 60 213 ± 39 113 ± 46 0.563 0.993 0.633
F 49 ± 14 122 ± 40 119 ± 25 0.654 0.675 0.999
Eating (s) M 2977 ± 443 3149 ± 460 2320 ± 285 0.983 0.776 0.669
F 1743 ± 289 2171 ± 268 2674 ± 371 0.902 0.619 0.868
8 weeks dark phase activity
sex WT-Veh R6/2-Veh R6/2-XJB WT-Veh vs R6/2-Veh WT-Veh vs R6/2-XJB R6/2-Veh vs R6/2-XJB
p value p value p value
Climbing (s) M 13340 ± 3442 6094 ± 1155 10127 ± 1309 0.012 0.999 0.251
F 20398 ± 2174 13952 ± 3125 8689 ± 1496 0.029 <0.001 0.086
Locomotor activity (s) M 3119 ± 286 1775 ± 180 2386 ± 271 <0.001 0.06 0.134
F 2523 ± 184 1888 ± 151 1790 ± 213 0.015 0.005 0.889
Immobility (s) M 33353 ± 4608 48438 ± 1882 42234 ± 2622 0.008 0.055 0.224
F 29209 ± 1024 42444 ± 934 44173 ± 2108 <0.001 <0.001 0.66
Rearing (s) M 2125 ± 409 2385 ± 321 2891 ± 266 0.75 0.099 0.347
F 1687 ± 377 1819 ± 488 2473 ± 477 0.963 0.277 0.406
Grooming (s) M 6855 ± 1056 4167 ± 538 4607 ± 585 0.016 0.048 0.879
F 8644 ± 789 5502 ± 535 5212 ± 608 0.004 0.002 0.944
Drinking (s) M 226 ± 53 438 ± 83 305 ± 138 0.146 0.751 0.455
F 269 ± 62 266 ± 84 340 ± 84 0.999 0.265 0.252
Eating (s) M 5260 ± 1034 4452 ± 839 3755 ± 722 0.683 0.277 0.751
F 2357 ± 625 3180 ± 1199 4425 ± 904 0.687 0.109 0.429
14 weeks light phase activity
sex WT-Veh R6/2-Veh R6/2-XJB WT-Veh vs R6/2-Veh WT-Veh vs R6/2-XJB R6/2-Veh vs R6/2-XJB
p value p value p value
Climbing (s) M 1784 ± 784 1262 ± 479 1385 ± 736 0.975 0.985 0.999
F 1765 ± 707 2561 ± 473 932 ± 261 0.953 0.957 0.834
Locomotor activity (s) M 1302 ± 135 1552 ± 291 965 ± 375 0.917 0.856 0.629
F 1002 ± 129 1612 ± 717 1587 ± 229 0.754 0.771 0.999
Immobility (s) M 61240 ± 2043 56347 ± 1799 54501 ± 7236 0.742 0.573 0.958
F 65539 ± 1242 56161 ± 6205 53045 ± 4214 0.249 0.097 0.848
Rearing (s) M 722 ± 111 2521 ± 606 2626 ± 886 0.176 0.103 0.992
F 803 ± 222 2245 ± 848 1981 ± 752 0.682 0.567 0.981
Grooming (s) M 5593 ± 635 2784 ± 916 4424 ± 1508 0.194 0.735 0.551
F 5196 ± 285 3600 ± 650 1704 ± 836 0.367 0.018 0.251
(Continued)
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Discussion
There are no effective therapeutic compounds available that offset the devastating progressive
effects of HD. Previously, we have reported that the synthetic radical and electron scavenger,
XJB-5-131, attenuates oxidative damage and blocks decline in rotarod performance of HdhQ
(150/150)mice, if treatment begins before [9] or after the phenotype develops [8]. Here, we
asked whether XJB-5-131 can improve the outcome in R6/2 mice, an HD model with an early
onset and severe phenotype. Chronic treatment of R6/2 mice produced a number of improve-
ments in the phenotype. The strongest effect of the drug on behavioural parameters was seen
with the fixed speed rotarod, where R6/2 XJB-5-131-treated male mice performed significantly
better than vehicle-treated R6/2 mice. Although the effect was weaker in female mice, drug
treatment still ameliorated the decline in motor performance on the rotarod. Additional
improvements in the phenotype were seen with maintenance of body weight and temperature.
The behavioural features in the open field were complex even between genotype activity, and
XJB-5-131 did not appear to improve it. When taken together, however, treatment with the
mitochondrial-specific compound XJB-5-131 improved several key features in R6/2 mice. Met-
abolic deficits are known to be a feature of both HD patients and R6/2 mice [34, 35]. We did
not measure metabolism in the mice in the current study, but the ability of XJB-5-131-treated
mice to maintain weight, temperature and muscular strength is indicative of a restoration of
the energy imbalance. XJB-5-131 did not extend survival at the dose used. However, the overall
benefits in late onset features in HdhQ(150/150)mice and in severe, early onset features in R6/
2 mice, taken together, suggest that XJB-5-131 has therapeutic value during the lifetime of
these animals.
A second important finding from the analysis was the marked sex differences in response
to treatment with XJB-5-131, a result that mirrored results from some of our earlier
Table 1. (Continued)
Drinking (s) M 55 ± 24 424 ± 210 782 ± 610 0.914 0.708 0.919
F 72 ± 10 927 ± 571 1185 ± 257 0.457 0.275 0.928
Eating (s) M 2321 ± 553 3620 ± 1098 5316 ± 1998 0.817 0.36 0.711
F 1213 ± 247 3379 ± 1251 10334 ± 3706 0.73 0.013 0.061
14 weeks dark phase activity
sex WT-Veh R6/2-Veh R6/2-XJB WT-Veh vs R6/2-Veh WT-Veh vs R6/2-XJB R6/2-Veh vs R6/2-XJB
p value p value p value
Climbing (s) M 10374 ± 3678 3398 ± 1346 3048 ± 882 0.025 0.019 0.988
F 14887 ± 4628 5243 ± 689 3025 ± 1104 0.008 0.002 0.716
Locomotor activity (s) M 3585 ± 478 3106 ± 738 1682 ± 426 0.733 0.02 0.089
F 3089 ± 305 2833 ± 1118 2306 ± 468 0.951 0.631 0.81
Immobility (s) M 34807 ± 4980 40364 ± 4001 43036 ± 5480 0.682 0.442 0.914
F 31671 ± 3252 39949 ± 4463 41604 ± 2801 0.332 0.213 0.954
Rearing (s) M 2554 ± 446 3641 ± 629 3263 ± 451 0.512 0.706 0.905
F 1888 ± 552 3438 ± 1709 3014 ± 1146 0.705 0.522 0.951
Grooming (s) M 6516 ±757 3016 ± 1043 5301 ± 1423 0.088 0.717 0.326
F 7718 ± 999 3607 ± 1136 2251 ±686 0.006 <0.001 0.48
Drinking (s) M 214 ± 71 1173 ± 644 1799 ± 1284 0.554 0.217 0.774
F 226 ± 71 1774 ± 942 1902 ± 433 0.097 0.068 0.982
Eating (s) M 4716 ± 913 5268 ± 2045 6507 ± 1770 0.964 0.684 0.832
F 2230 ± 403 6318 ± 2620 10324 ± 1330 0.342 0.027 0.356
https://doi.org/10.1371/journal.pone.0194580.t001
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experiment with HdhQ(150/150) [8]. Drug treatment produced stronger beneficial effects in
male mice with regard to maintenance of weight, locomotors activity and performance in the
fixed speed rotarod task. There were indications with glycosuria testing at 12 weeks, and eating
data at 14 weeks, that treatment with XJB-5-131 may have exacerbated elements of the pheno-
type in female mice. However, female R6/2 mice treated with XJB-5-131 showed better perfor-
mance than male drug-treated mice on the accelerating rotarod, indicating that the effect of
Fig 7. LABORAS analysis of activity at 8 weeks of age. Treatment with XJB-5-131 improved the phenotype in male
R6/2mice in terms of time climbing (A), and time active (B).  p<0.05,  p<0.01,  p<0.001. Grey bars, WT; white
bars, R6/2-Veh; black bars, R6/2-XJB. Data are mean ± SEM. Mouse numbers: WT male, WT female, R6/2-Veh male,
R6/2-Veh female, n = 8. R6/2-XJB male, n = 7; R6/2-XJB female, n = 9.
https://doi.org/10.1371/journal.pone.0194580.g007
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XJB-5-131 on the R6/2 phenotype was complex. It is not clear why XJB-5-131 should produce
different results in male and female mice. However, we have shown recently that precondition-
ing R6/2 mice with the succinate dehydrogenase inhibitor 3-nitropropionic acid also has sex-
dependent effects, but in this case the protective effect was more evident in female than male
mice [36]. Sex differences in behaviour and response to treatments have also been shown in a
range of other mouse models of HD. For example, female YAC128 mice live longer than male
mice [37]. In the 140 CAG knock-in model, female mice groomed more frequently, and dis-
played increased dark phase running, while male mice showed decreased climbing [38]. Male
N171-82Q mice perform less well on the rotarod than female mice [39]. Our own work has
shown marked differences in the response of male and female R6/2 mice to environmental
enrichment [40]. Taken together, our data suggest that given the obvious sex differences in
Table 2. Glycosuria at 12 and 16 weeks. Numbers of mice per group showing glycosuria.
12 weeks (n = 6) 16 weeks (n = 4)
WT-Veh male 0 0
WT-Veh female 0 0
R6/2-Veh male 1 4
R6/2-XJB male 3 4
R6/2-Veh female 1 4
R6/2-XJB female 5  4
 p<0.01, comparison of R6/2-Veh and R6/2-XJB female mice.
https://doi.org/10.1371/journal.pone.0194580.t002
Table 3. The number of mice per group during the experiment.
number of mice per group
WT-Veh male WT-Veh female R6/2-Veh male R6/2-XJB male R6/2-Veh female R6/2-XJB female
age (weeks)
4 8 8 8 7 8 9
5 8 8 8 7 8 9
6 8 8 8 7 8 9
7 8 8 8 7 8 9
8 8 8 8 7 8 9
9 6 6 6 6 6 6
10 6 6 6 6 6 6
11 6 6 6 6 6 6
12 6 6 6 6 6 6
13 4 4 4 4 4 4
14 4 4 4 4 4 4
15 4 4 4 4 4 4
16 4 4 4 4 4 4
17 4 4 4 4 4 4
18 4 4 3  4 4 4
19 4 4 1  4 2  3 
20 4 4 0 2  2  1 
21 4 4 0 2  1  1 
22 4 4 0 1  0 1 
Reductions in numbers are where mice were killed for timecourse histology, except where indicated by:
’ which represents mice killed as a result of ill health.
https://doi.org/10.1371/journal.pone.0194580.t003
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phenotypically altered behaviour in HD mice, it should not be assumed that any single thera-
peutic approach or dose will work the same way or to the same extent in both sexes.
Fig 8. Survival analysis for the R6/2 mice. Only mice kept beyond the 12 weeks timepoint are represented. There was
no effect of XJB-5-131 on age at death in either male (B) or female (C) mice.
https://doi.org/10.1371/journal.pone.0194580.g008
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Fig 9. Somatic CAG expansion is suppressed in R6/2 mice by XJB-5-131 treatment. The CAG repeat lengths in the
striatum (A) and cerebellum (B) of R6/2 mice at 8 or 12 weeks with treatment beginning at 4 weeks. Expansions were
observed as a shift in the size distribution of CAG lengths for each mouse (red) compared to the size at weaning (blue).
Treatment with XJB-5-131 suppresses expansion in both brain regions. The gender of the mice is designated by ‘M’ (male)
XJB-5-131 relieves Huntington’s disease
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We have previously published work showing that suppression of somatic expansion reduces
pathophysiology and significantly delays the onset of motor decline in late onset HdhQ(150/
150) animals [10], and that treatment with XJB-5-131 reduces both the somatic expansion and
the disease phenotype of HdhQ(150/150) animals [8–10]. Somatic expansion in R6/2 mice was
absent at 8 weeks of age, a time associated with little to no decline in physical parameters or
behavioural features of disease. By 12 weeks, however, the CAG expansion in R6/2 mice of
both sexes was supressed by XJB-5-131, as was inclusion formation. Suppression of somatic
expansion correlated with the improvement in phenotypes in treated animals. Furthermore,
XJB-5-131 also suppressed inclusion formation in the brains of R6/2 animals, a biomarker for
disease progression. The ability of treatment to suppress these features of disease bolsters the
idea that treatment has therapeutic value during the lifetime of these animals.
In summary, XJB-5-131 remains a promising compound. In HdhQ(150/150)mice, a milder,
late onset model of HD, XJB-5-131 suppressed motor decline in animals treated either pre- or
post- onset of phenotype. Here, we have shown that chronic treatment of R6/2 mice with XJB-
5-1-131 caused some improvement in the motor deficit and weight loss seen in R6/2 mice
(especially male mice), reduced the loss of body temperature, reduced the number of inclu-
sions and slowed CAG repeat expansion. We suggest that XJB-5-131 is worthy of further study
to elucidate the mechanisms that bring about the beneficial effects, and to determine why
there were sex differences in the outcomes.
Supporting information
S1 Fig. Raw data for the sizing of CAG repeats from mice tails at time of weaning. The raw
data from the electroporation sizing gels for the CAG repeat regions (from GeneMapper).
Each sample (mouse) identifier is an alphanumeric code eg. BRM2085t, where ‘M’ indicates
the sex (male), and ‘t’ indicates tail DNA. The x axis units are the length of the PCR product
(in base pairs). The y axis is signal intensity. The CAG triplet repeat number is calculated as
(CAG)n = (PCR size(bp)-122)/3 1.0425+1.2088. This calculation takes into account the 3’ and
5’ non-repeat portions, and a normalization factor for CAG repeats running in the sizing gels.
(TIF)
S2 Fig. Raw data for the sizing of CAG repeats from mouse striatum at indicated ages. The
raw data from the electroporation sizing gels for the CAG repeat regions (from GeneMapper).
Each sample (mouse) identifier is an alphanumeric code eg. BRM2085t, where ‘M’ indicates the
sex (male), and ‘s’ indicates striatum DNA. The x axis units are the length of the PCR product
(in base pairs). The y axis is signal intensity. The CAG triplet repeat number is calculated as
(CAG)n = (PCR size(bp)-122)/3 1.0425+1.2088. This calculation takes into account the 3’ and
5’ non-repeat portions, and a normalization factor for CAG repeats running in the sizing gels.
(TIF)
S3 Fig. Raw data for the sizing of CAG repeats from mouse cerebellum at indicated ages.
The raw data from the electroporation sizing gels for the CAG repeat regions (from GeneMap-
per). Each sample (mouse) identifier is an alphanumeric code eg. BRM2085t, where ‘M’ indi-
cates the sex (male), and ‘c’ indicates cerebellar DNA. The x axis units are the length of the
or ‘F’ (female). (C) The impact of XJB-5-131 on expansion in the striatum as determined using a quantile analysis [10]. The
combined size distribution from the striatum in treated and untreated groups was divided into 99 cells. Shown is the size
differences in untreated v. treated striatum along the distribution at 12 weeks. Red are cells in which there was a significant
increase in the untreated versus the treated (p < 0.05). Blues are cells with no significant increases. Bracketed lines represent
1 SE (Standard Error of the Mean). The significance is listed for each cell in S2 and S3 Tables. (n = 3 mice per treatment
group).
https://doi.org/10.1371/journal.pone.0194580.g009
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Fig 10. Neuronal loss and inclusion bodies assessed by histology. There was no observable neurodegeneration (loss of neurons = green
stained cells; neurons labelled with anti-NeuN antibody) in the striatum of R6/2mice by 12 weeks of age (A). Neuronal numbers in the
striatum of R6/2mice are similar to age-matched WT mice (B). Inclusion bodies (of ubiquitinated protein, labelled with anti-ubiquitin
antibody) were increased in R6/2mouse striatum compared to matched WT (at 12 weeks). This increase was inhibited by treatment with XJB-
5-131 (C). These inclusion bodies are observed in both the nuclear (colocalize with nuclear label = DAPI in (C), blue bars) and the cytosolic
(non-nuclear, red bars) compartments (D).
https://doi.org/10.1371/journal.pone.0194580.g010
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PCR product (in base pairs). The y axis is signal intensity. The CAG triplet repeat number is
calculated as (CAG)n = (PCR size(bp)-122)/3 1.0425+1.2088. This calculation takes into
account the 3’ and 5’ non-repeat portions, and a normalization factor for CAG repeats running
in the sizing gels.
(TIF)
S1 Table. The impact of XJB-5-131 on the performance of R6/2 animals in additional open
field behaviour at 7, 12 and 17 weeks. Results of Significant difference are shown. p<0.05, 
p<0.01,  p<0.001.
(DOCX)
S2 Table. Difference in the repeat size distribution in the striatum of the treated and
untreated mice (compared as percentiles). ( for p< 0.05) (SE = Standard Error of the
Mean).
(DOCX)
S3 Table. Difference in the repeat size distribution in the cerebellum of the treated and
untreated mice (compared as percentiles). ( for p< 0.05) (SE = Standard Error of the
Mean).
(DOCX)
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